Subscribe
nitpicker
nitpicker / shutterstock.com
5 May 2020Asia-Pacific

Setback for Gilead in GSK HIV antiviral suit

An Australian federal judge has thrown out a challenge by  Gilead Sciences to the wording of infringement claims made by a  GlaxoSmithKline (GSK) subsidiary.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
GSK, Amgen want SCOTUS to protect genus claims
18 November 2020   Patent law experts and pharmaceutical companies have lent their support to Merck Sharp & Dohme in its effort to confirm the patent-eligibility of genus claims at the US Supreme Court.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Americas
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Americas
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Americas
GSK, Amgen want SCOTUS to protect genus claims
18 November 2020   Patent law experts and pharmaceutical companies have lent their support to Merck Sharp & Dohme in its effort to confirm the patent-eligibility of genus claims at the US Supreme Court.

More on this story

Americas
GSK, Amgen want SCOTUS to protect genus claims
18 November 2020   Patent law experts and pharmaceutical companies have lent their support to Merck Sharp & Dohme in its effort to confirm the patent-eligibility of genus claims at the US Supreme Court.

More features

Startup challenges rival over brain monitoring tech at ITC
UKIPO rejects Boehringer’s SPC for horse inhaler
WilmerHale gains partner with ‘deep expertise’
Bayer, Orion take on Indian generic over $117bn drug
‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court